Madhya Pradesh-based contract development and manufacturing organisation (CDMO) Symbiotec Pharmalab has successfully raised ₹526.20 crore through its anchor book, demonstrating strong institutional confidence ahead of its ₹1,757 crore initial public offering. The company allocated 53,25,909 equity shares to 34 anchor investors at ₹988 per share, with the anchor book closing a day before the IPO opens for public subscription. The anchor investor allocation includes marquee names such as Citigroup Global Markets, BNP Paribas Financial Markets – ODI, Baroda BNP Paribas Health and Wellness Fund, Tata AIA Life Insurance Company, Singularity Equity Fund I, ICICI Prudential Smallcap Fund, HDFC Pharma and Healthcare Fund, HDFC MNC Fund, Motilal Oswal Small Cap Fund, Mirae Asset Health Care Fund, Mirae Asset Multi Asset Allocation Fund, and Edelweiss Large Cap Fund. Insurance companies Tata AIA Life, Bajaj Life, and Bharti AXA Life also participated, purchasing 4.25 lakh shares worth ₹42 crore. Among the notable investors, 40% of the total anchor portion was reserved for domestic mutual funds, life insurance companies and pension funds, with 33.33% allocated to domestic mutual funds and 6.67% to life insurance companies and pension funds. The anchor round saw participation from foreign portfolio investors, insurance companies, mutual fund houses, an alternative investment fund and an NBFC.
Pharmaceutical and biotechnology company Symbiotec Pharmalab, backed by Rosewood Investments and Motilal Oswal, has announced the price band for its initial public offering (IPO). The Madhya Pradesh-based company has fixed the price band at ₹933-₹988 per equity share of face value ₹2. Investors can bid for a minimum of 15 shares and in multiples thereafter. At the upper end of the price band, the minimum investment required by a retail investor is ₹14,820 for 15 shares. The IPO comprises a fresh issue of ₹150 crore and an offer-for-sale (OFS) of shares worth up to ₹1,607 crore by existing shareholders. The IPO is scheduled to open for subscription on August 24, 2026, and close on August 27, 2026. The issue is expected to list on both BSE and NSE on September 1, 2026, with allotment likely to be finalised on August 28, 2026. The price band has been fixed at ₹933-988 per equity share, valuing the company at around ₹6,348.5 crore at the upper limit. The allocation to anchor investors for the IPO is scheduled to take place on August 21, 2026.
Largest shareholders Rosewood Investments and Motilal Oswal have offloaded 10.43% stake in Symbiotec Pharmalab ahead of its IPO opening. Both investor selling shareholders transferred a total of 65.57 lakh equity shares to 17 other investors at the upper end of price band on August 19, 2026. As a result, Rosewood Investments' shareholding has reduced to 30.34% (1.9 crore equity shares) from 34.78%, while India Business Excellence Fund III's stake has decreased to 18.14% (1.13 crore shares) from 24.16%. Think Investments' Think India Opportunities Master Fund and Dymon Asia Capital's Dymon Asia Multi-Strategy Investment emerged as major buyers, acquiring 27.83 lakh shares representing 2.82% and 1.61% stakes respectively. ValueQuest Investment Advisors was the largest buyer amongst investors, acquiring 20.24 lakh shares (3.22% of pre-offer paid-up equity) through ValueQuest Founders Conviction LVF and ValueQuest Fastercap Fund II from Motilal Oswal. The company will not receive any proceeds from the offer for sale, with all proceeds accruing to respective selling shareholders after deducting their share of offer-related expenses and applicable taxes.
The IPO comprises a fresh issue of ₹150 crore and an offer-for-sale (OFS) of shares worth up to ₹1,607 crore by existing shareholders. Promoter Satwani Holdings, along with investors Rosewood Investments and India Business Excellence Fund - III, will participate in the OFS. The promoter group's stake will fall to 33.3% after the IPO from the current 36.4%. The anchor investor portion will open on August 21, while the public issue will remain open until August 27. The company has reduced its OFS size from ₹2,030 crore while keeping the fresh issue component unchanged at ₹150 crore, as per the red herring prospectus filed on August 18. The company is offering eligible employees a ₹90-per-share discount on bids made through the employee reservation portion. Half of the net public issue size has been reserved for qualified institutional buyers, while 35% shares have been allocated for retail investors, and the remaining 15% shares for non-institutional investors. The IPO lot size is set at 15 equity shares with bidding in multiples thereafter. The issue comprises a fresh issue of equity shares worth up to ₹150 crore and an OFS component amounting to ₹1,607 crore.
Symbiotec claims a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs), with a global volume market share of 36.2% in corticosteroid APIs and 44.2% in steroidal-hormone APIs. The company operates as a contract development and manufacturing organisation (CDMO) for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms - organic chemistry, biotechnology and complex injectables. As of March 2026, the company had two operational industrial-scale API manufacturing facilities in Madhya Pradesh, including two API manufacturing facilities in Rau and Pithampur with a maximum chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres. The company has also commissioned two additional manufacturing facilities at Ujjain and Mhow in Madhya Pradesh. The company is currently expanding biologics capacity by adding a proposed dedicated 14 KL fermentation capacity to cater to increasing demand for GLP-1 and insulin. It competes with four listed Indian peers - Concord Biotech, Divi's Laboratories, Cohance Lifesciences and Laurus Labs. Research-driven manufacturing, quality and sustainability form key elements of its business strategy, with manufacturing operations securing approvals from several international regulatory bodies including the US FDA, EU-GMP authorities and South Korea's Ministry of Food and Drug Safety.
For the quarter ended June 2025, Symbiotec reported a profit of ₹29.9 crore on revenue of ₹203.1 crore. For FY25, the company reported a profit of ₹96.8 crore, down 3.3% from ₹100 crore in the previous financial year. However, revenue rose 5% to ₹751.6 crore from ₹716.2 crore during the same period. For the financial year ended March 2026, the company reported profit of ₹110 crore, growing 13.6% from ₹96.8 crore in the previous fiscal. Revenue soared 15.6% during the same period to ₹869.1 crore from ₹751.6 crore. The company's profit grew at a compound annual growth rate (CAGR) of 4.81% to ₹109.9 crore in FY6 from FY4, while revenue increased at a CAGR of 10.16% during the same period to ₹869.1 crore. Of the fresh issue proceeds, ₹112.5 crore will be used towards partial repayment of debt, while the remaining funds will be utilised for general corporate purposes. The IPO is valued at a steep 52 times FY6 diluted EPS at the upper price band.
According to market sources, the grey market premium (GMP) of the Symbiotec Pharmalab IPO stood at ₹320 on Friday, indicating that the stock could list at a premium of around 32.40% over the upper end of the issue price band of ₹988. The IPO is set to open on August 24, 2026, marking the 16th mainboard issue to hit Dalal Street this month. Twelve issues have already debuted on the exchanges, with all of them currently trading above their respective issue prices. As part of the OFS, promoter Satwani Holdings LLP and investors Rosewood Investments and India Business Excellence Fund-III will offload shares. The book-running lead managers include JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, and Nomura Financial Advisory and Securities (India), while MUFG Intime India Pvt. Ltd. serves as the registrar. Investors who receive allotment will see shares credited to their demat accounts by Monday, August 31, 2026, while refunds for unsuccessful bidders will also be initiated on the same day.
